CONMED Corporation — Form 10-Q Summary
Business Context and Reporting Period
CONMED is a medical technology company providing surgical devices and equipment for minimally invasive procedures across orthopedic and general surgery. This unaudited filing covers the three months ended March 31, 2022, compared with the three months ended March 31, 2021.
Approximately 83% of revenue came from single-use products, and international sales represented approximately 46% of consolidated sales. The company operates as one reportable segment.
Financial Performance and Position
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Net sales | $242.3 million | $232.7 million | 4.1% increase |
| Gross profit | $136.0 million | $128.4 million | 5.9% increase |
| Gross margin | 56.1% | 55.2% | Up 90 basis points |
| Income from operations | $22.4 million | $20.1 million | 11.8% increase |
| Net income | $15.0 million | $9.9 million | 51.8% increase |
| Diluted EPS | $0.47 | $0.31 | Increase |
| Net cash from operating activities | $0.3 million | $22.3 million | Significant decrease |
General surgery revenue increased 7.4% to $134.8 million, driven primarily by AirSeal and advanced endoscopic technologies. Orthopedic surgery revenue increased 0.3% to $107.5 million. Single-use product revenue increased 7.5% to $201.5 million, while capital product revenue declined 9.7% to $40.8 million.
Selling and administrative expense increased to $102.9 million from $98.3 million, and research and development expense increased to $10.7 million from $10.0 million. The effective tax rate was 14.2%, compared with a tax benefit rate of 1.3% in the prior-year quarter.
Cash and cash equivalents were $24.9 million at March 31, 2022, compared with $20.8 million at December 31, 2021. Inventories increased to $253.7 million from $231.6 million as the company built inventory to mitigate supply-chain risks. Capital expenditures were $3.7 million.
Total debt was $715.8 million, including $151.0 million drawn on the revolving facility, $224.6 million outstanding under the term loan, and $341.0 million of convertible notes. Revolving-facility availability was $431.8 million, with approximately $2.2 million reserved for letters of credit. The company was in compliance with its debt covenants.
Material Changes Versus the Prior Comparable Period
- Revenue growth was led by general surgery and single-use products; capital product sales declined.
- Gross margin improved primarily from higher sales and product mix, although the company recorded $10.0 million of unfavorable production variances related to inflation, raw materials, freight and other production costs that were deferred in inventory.
- Interest expense declined to $5.0 million from $10.4 million, partly because 2021 included $2.5 million of convertible-debt discount amortization and because of lower borrowing costs.
- Operating cash flow fell to $0.3 million, principally due to inventory investment, collection timing for accounts receivable and higher incentive compensation payments.
- The company adopted ASU 2020-06 on January 1, 2022. Adoption increased reported long-term debt by approximately $22.6 million, reduced additional paid-in capital by approximately $37.9 million, increased beginning retained earnings by approximately $20.8 million after tax, reduced Q1 interest expense by approximately $2.6 million and increased diluted EPS by approximately $0.07.
- The prior-year quarter included $0.4 million of restructuring costs that did not recur.
Outlook, Risks, Contingencies and Unusual Items
Management stated that COVID-19 continued to affect procedure volumes, hospital staffing and supply chains, including stay-at-home orders in China. Inflationary pressures and supply-chain challenges increased manufacturing and operating costs and are expected to continue throughout 2022. Management cautioned that deferred unfavorable production variances could reduce gross margins when the related inventory is sold.
The company stated that available cash, operating cash flow and revolving-credit capacity should be adequate for anticipated working capital, debt service, capital expenditures, dividends and share repurchases. However, it may need to reduce costs or refinance debt depending on future conditions.
CONMED had no direct operations in Russia or Ukraine; related distributor revenue was not material, and the company fully reserved $0.6 million of outstanding receivables from those territories. Higher oil prices related to the conflict contributed to inflationary pressures.
Material contingencies include the EndoDynamix litigation, Georgia actions involving alleged ethylene oxide exposure, insurance-coverage litigation, product liability and other ordinary-course claims. The company has not recorded potential losses for the principal matters because management does not believe losses are probable or cannot estimate a range of loss.
On May 4, 2022, after quarter-end, CONMED agreed to acquire In2Bones Global for an upfront cash payment of $145 million, subject to adjustments, plus potential earn-out payments of up to $110 million based on revenue targets.
The company declared a quarterly dividend of $0.20 per share and had $37.4 million remaining under its $200 million share-repurchase authorization. No shares were repurchased under the program during the quarter.
Important Facts for Investors to Verify
- Whether COVID-19-related procedure disruptions, staffing shortages and supply-chain constraints affect subsequent revenue and procedure volumes.
- The timing and magnitude of recognition of the $10.0 million of unfavorable production variances deferred in inventory.
- Liquidity and leverage following the planned In2Bones acquisition, including the treatment of earn-out obligations.
- The effect of the 2022 convertible-debt accounting adoption on future diluted share counts, EPS and reported debt.
- Progress and potential exposure in the EndoDynamix, ethylene oxide and insurance-coverage litigation.
- Whether inflation, freight, raw-material and other operating costs pressure gross margins during the remainder of 2022.
- Compliance with debt covenants and availability under the revolving credit facility as borrowings and acquisition spending change.